• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

    8/2/21 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email

    Company appoints six new members to SAB to maximize the company's impact in the proteomics domain

    908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod Marto (Dana Farber Cancer Institute/Harvard Medical School) and Prof. Josh Coon (University of Wisconsin-Madison).

    "We're exceptionally fortunate to welcome this esteemed group of scientists to our advisory board," said Professor J. Michael Ramsey, co-chair of the 908 Devices Scientific Advisory Board. "The new panel's expertise spans remarkably diverse segments in the proteomics revolution, from fundamental host-pathogen interactions in infectious disease to degenerative disease pathways and protein biotherapeutics. I can't think of a finer group to share their vision and insights, and maximize the impact of 908 Devices developments in the proteomics domain."

    908 Devices has recently expanded its platform capabilities for the rapid and high-fidelity analysis of extraordinarily complex samples of biological origin. This newly-formed proteomics panel will be invaluable to the continued advancement of our platform mass spec and microfluidic technology and its application to contemporary problems in proteomics-oriented life science research. "This is a remarkable group of thought-leaders in this domain," said Christopher D. Brown, CTO and co-founder of 908 Devices. "The diversity in their areas of expertise within proteomics is a reflection of the myriad protein-based opportunities in front of us with our core microfluidic and mass spectrometry technologies."

    The roster of new Scientific Advisory Board members includes:

    • Ileana Cristea - Henry L. Hillman Professor of Molecular Biology, Princeton University: Dr. Cristea's research lies at the interface between virology and proteomics, with the aim of building an understanding of viral infection from a comprehensive proteomics perspective. Dr. Cristea is a member of numerous organizations, being on the Executive Board of the U.S. Human Proteome Organization, Chair of the Biology/Disease-driven Human Proteome Project, and on the Editorial Boards of the Journal of Proteome Research, mSystems, and Molecular & Cellular Proteomics.
    • Jennifer E. Van Eyk – Professor of Medicine, Cedars Sinai Medical Center; Erika J. Glazer Chair in Women's Heart Health Director, Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences and Precision Biomarker Labs: Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Dr. Van Eyk's laboratory aims to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.
    • Anne-Claude Gingras – Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto: Dr. Gingras is an expert in mass spectrometry-based proteomics, enabling the identification and quantification of proteins from biological samples. Her lab specializes in developing tools to better understand how proteins associate with one another to perform their functions. She is a deputy editor at the journal Molecular & Cellular Proteomics, and a member of the Advisory Boards for Molecular Cell and Molecular Systems Biology.
    • Jesper Olsen – Professor, and Vice Director of the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen: During his PhD, Dr. Olsen was involved in developing high-resolution mass spectrometry-based proteomics methods. Since 2009, Dr. Olsen has headed a group at the newly established Novo Nordisk Foundation Center for Protein Research (CPR) at University of Copenhagen. Dr. Olsen has received a number of research awards including the Max Planck Institute for Biochemistry Junior Research Award and HUPO Young Investigator Award in Proteomic Sciences.
    • Renã Robinson – Associate Professor of Chemistry, Vanderbilt University; Dorothy J. Wingfield Phillips Chancellor's Faculty Fellow: Dr. Robinson's research is breaking new ground in understanding the science of aging and neurogenerative diseases such as Alzheimer's through the large-scale and high-throughput analysis of proteins and lipids with mass spectrometry-based methods. She has developed a number of novel analytical techniques for the proteomic and lipidomic analysis of a range of biological matrices.
    • John Yates – Professor of Molecular Medicine, Scripps Research Institute: Dr. Yates' laboratory has invented a number of critical technologies considered essential to contemporary mass spectrometry-based proteomics, including the SEQUEST algorithm for peptide sequencing, and data independent analysis methods, and pioneered a number proteomics approaches including shotgun proteomics. He has won a number of awards in the areas of chemical biology and mass spectrometry over his distinguished career at Scripps, and published more than 700 scientific publications in addition to being the Editor-in-Chief of the Journal of Proteome Research.

    To learn more, visit www.908Devices.com.

    About 908 Devices

    908 Devices (NASDAQ:MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005081/en/

    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Knopp Kevin J. bought $64,200 worth of shares (10,000 units at $6.42), increasing direct ownership by 2% to 508,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/13/24 4:42:46 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $57,700 worth of shares (10,000 units at $5.77), increasing direct ownership by 2% to 498,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/10/24 6:36:05 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $58,300 worth of shares (10,000 units at $5.83), increasing direct ownership by 2% to 488,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/9/24 4:34:35 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Financials

    Live finance-specific insights

    See more
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

      Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

      3/4/25 7:45:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MASS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical Detection

      The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ

      4/30/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

      Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea

      4/22/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MASS
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      11/13/24 8:05:47 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Stephens initiated coverage on 908 Devices with a new price target

      Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

      2/7/23 6:37:28 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SVB Leerink reiterated coverage on 908 Devices with a new price target

      SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously

      3/8/22 4:31:59 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

      908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

      3/2/22 4:30:00 PM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

      Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod

      8/2/21 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by 908 Devices Inc.

      DEFA14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:03:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by 908 Devices Inc.

      DEF 14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:00:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form SCHEDULE 13G filed by 908 Devices Inc.

      SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

      4/7/25 4:18:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      7/8/24 4:32:41 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Awm Investment Company, Inc. claimed ownership of 5,199,924 shares (SEC Form 3)

      3 - 908 Devices Inc. (0001555279) (Issuer)

      3/14/25 4:27:06 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by President and CEO Knopp Kevin J.

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:30 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Chief Financial Officer Griffith Joseph H. Iv

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials